Dermira Inc (NASDAQ:DERM) and UCB, have announced the results from a 16-week investigation of the CIMPASI-1 and CIMPASI-2 Phase 3 trials. The announcement was made at the 75th Annual Meeting of the American Academy of Dermatology that took place in Orlando, Florida. Dermira Inc is one of the biotech stocks listed at SEC.
According to the results from the study, CIMZIA® showed great improvement in patient with mild-to-severe psoriasis versus placebo. In addition to co-primary endpoints reported in previous trials, new data presented at the AAD shows a big number of patients registered 90% and more improvement from the baseline. Results from RAPID-PsA Phase 3 trial were presented showcasing the long-term impact of CIMZIA in active psoriatic arthritis (PsA) patients.
Dermira chief development Officer Luis Peña said the clinical results support the company’s belief that CIMZIA will at one point be of benefit to people with mild-to-severe plaque psoriasis. She said Dermira is fully committed to offering patients with new and improved treatment options.
UCB Executive Vice President and Head of Immunology said the trial is motivated by the desire to provide values to patients. He adds that the results demonstrate the company’s expending immunology portfolio for plaque psoriasis and psoriatic arthritis patients.
The results from the CIMPASI-1 and CIMPASI-2 clinical trials offer important analysis into the probability of being used for treatment of mild to severe chronic plaque psoriasis in adults. According to researchers privy to the study, CIMZIA reported significant improvements in PASI 75, PASI 90 and PGA end points at week 16 as compared to placebo.
The company also presented topline results from the trial. The trials examined the percentage of patients who reported 75% and above improvement from baseline based on PASI 75 as well as the number of patients reporting an improvement of at least two points on the PGA scale.
The most prevalent side effect from the trials through week 16 was upper respiratory tract infections. The adverse effects were however infrequent. Both trials recorded a consistent adverse event profile. CIMZIA has not been approved for treatment of psoriasis in any country globally. Dermira, a top biotech stocks has patterned with a number of companies in several clinical trials, some of which are still in the process.